The Discovery of a New Drug Class for the Acute Treatment of Migraine

@article{Humphrey2007TheDO,
  title={The Discovery of a New Drug Class for the Acute Treatment of Migraine},
  author={Patrick P. A. Humphrey},
  journal={Headache: The Journal of Head and Face Pain},
  year={2007},
  volume={47}
}
  • P. Humphrey
  • Published 1 April 2007
  • Medicine
  • Headache: The Journal of Head and Face Pain
The history of the scientific ideas and events that led to the discovery of sumatriptan is outlined with personal reminiscences about individuals who influenced the approach. The development of sumatriptan revolutionized the acute treatment of migraine and led to the availability of a number of other triptans. The anti‐migraine effects of all the triptans are mediated via 5‐HT1B, and possibly 5‐HT1D receptors, which transduce their effects via G; proteins. This suggests that agonists at other… 
Triptan efficacy in migraine attacks: from appropriate diagnosis to metabolic profiles and pharmacogenomics
TLDR
The use of a variety of endpoints for a certain drug, measuring treatment success in terms of both efficacy and tolerability, should aid in the selection of agents that can offer patients the highest likelihood of consistent treatment success.
Current and emerging therapies for migraine prevention and treatment.
TLDR
This chapter discusses current and emerging strategies for migraine prevention and treatment in the light of the understanding of migraine pathophysiology and summarizes some of the findings and examines their clinical implications for emerging drug treatments.
Identifying New Antimigraine Targets: Lessons from Molecular Biology.
TLDR
The distribution and the expression of neuropeptides themselves, as well as certain ion channels, and most importantly how they may act in concert as modulators of excitability of both the trigeminal C neurons and the Aδ neurons are explored.
New Migraine and Pain Research
TLDR
Research into migraine has generated sophisticated hypotheses that encompass primary CNS dysfunction, trigeminovascular activation, pain perception and activation of associated neural circuits involved in affective functions providing a rich framework within which to design and test future migraine treatment strategies.
Finding New Drug Targets for the Treatment of Migraine Attacks
TLDR
This model has predicted efficacy of nitric oxide synthase inhibition and calcitonin gene-related peptide receptor blockade and should pay more attention to human models, although methods are different from normal target validation.
Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets
TLDR
This article focuses on the development of targets related to the CGRP system, and further includes novel targets such as the pituitary adenylate cyclase-activating peptide system, the serotonin 5-HT1F receptor, purinergic receptors, HCN channels, adenosine triphosphate-sensitive potassium channels, and the glutaminergic system.
Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine
TLDR
Current evidence concerning potential risks and interactions associated with concomitant use of drugs indicated for the abortive treatment of migraine, namely triptans and ditans, and more recently developed drugs used for the preventive treatment is reviewed.
Is selective 5‐HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?
TLDR
This review will be particularly focussed on the similarities and differences between the triptans and the ditans, their proposed sites of action, side effects and their cardiovascular risk profile.
Migraine pain: reflections against vasodilatation
TLDR
The evidence against vasodilatation as migraine pain generator is discussed and some findings which are suggested in support of a central (brain) origin of pain are suggested.
Side effects associated with current and prospective antimigraine pharmacotherapies
TLDR
This review considers the adverse (or potential) side effects produced by current and prospective antimigraine drugs, including medication overuse headache (MOH) produced by ergots and triptans, the side effects observed in clinical trials for the new gepants and CGRP antibodies, and a section discussing the potential effects resulting from disruption of the cardiovascular CGRPergic neurotransmission.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
The Pharmacology of the Novel 5-HT1-Like Receptor Agonist, GR43175
TLDR
Its vasoconstrictor action can be shown to be localized even further to arteriovenous anastomoses (shunts) within the carotid circulation, in such a way that blood flow to the brain as well as to extracerebral capillary beds remains unaffected or may even be increased.
[Treatment of migraine attacks with sumatriptan].
The serotonin agonist, sumatriptan, is a new, highly promising alternative treatment for migraine that has a vasoconstricting effect on the blood vessels dilated during an attack. In addition,
A rational approach to identifying a fundamentally new drug for the treatment of migraine
As early as about AD 50, Aretaeus of Cappadocia is said to have recognised the symptoms of what is now known as migraine, describing the characteristic unilateral headache associated with nausea and
MECHANISM OF MIGRAINE HEADACHE AND ACTION OF ERGOTAMINE TARTRATE
TLDR
The experiments described here were performed when the phenomena which characterize the onset of an attack, namely, scotomas, blurring of vision, paresthesias and aphasia, had already passed and had been supplanted by headache, so these results have no bearing on preheadache phenomena.
Comparative Trial of Serotonin Antagonists in the Management of Migraine
TLDR
The effectiveness of five different serotonin antagonists in the prevention of migraine was compared, and methysergide 3-6 mg.
Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5‐hydroxy‐tryptamine (5‐HT1B/1D) receptors
TLDR
It is established that naratriptan acts on central trigeminal neurones since sagittal sinus stimulation activates axons within the tentorial nerve and there are no inhibitory effects mediated within the trigemINAL ganglion.
5-HT1F Receptor Agonists in Acute Migraine Treatment: A Hypothesis
TLDR
Preclinical experiments and clinical observations argue for a role of selective 5-HT1F agonists in migraine, and selective 5- HT1F receptor agonists are effective in preclinical migraine models and are non-vasoconstrictive.
Neurogenic inflammation in the context of migraine
TLDR
Observations suggest that C GRP release with associated neurogenic dural vasodilation may be important in the generation of migraine pain, a theory that would ultimately be tested by the clinical testing of a CGRP receptor antagonist.
Treatment of Migraine Attacks with A Long-Acting Somatostatin Analogue (Octreotide, SMS 201-995)
TLDR
SMS 201-995 significantly improves the pain of migraine attacks, 2 h after the beginning of treatment, and a single dose of 100 μg given subcutaneously is an effective and well-tolerated agent for the treatment of migraine Attacks.
Plasma serotonin in migraine and stress.
TLDR
Kimball, Friedman, and Vallejo were unable to produce headache in migrainous subjects by the injection of serotonin or its precursor 5-hydroxytryptophan, but found that injection of these substances relieved spontaneous migraine headaches.
...
1
2
3
4
5
...